ExAblate treatment is indicated for use for essential tremor, tremor
dominant Parkinson's disease and neuropathic pain
TIRAT CARMEL, Israel, Dec. 4, 2012 /CNW/ - InSightec Ltd. announced that
its transcranial focused ultrasound system, ExAblate Neuro, has been
awarded the European CE mark for the treatment of neurological
disorders in the brain including essential tremor, Parkinson's disease
and neuropathic pain.
Millions of people suffer from neurological disorders which cause
significant disability and negatively affect their quality of life and
that of their caretakers. Treatment options for patients who do not
respond to drug treatments include deep brain stimulation,
radiofrequency ablation and radiosurgery which are invasive or involve
ionizing radiation and are associated with recognized risks: high doses
of ionizing radiation or high risk of complications and side effects
including infection, bleeding and collateral brain tissue damage.
"ExAblate offers great potential for treating brain disorders. Because
of its targeting accuracy, real time treatment monitoring and ability
to provide non- invasive brain treatment, there is hope that many
people who suffer from neurological diseases can benefit from this
treatment," said Dr. Kobi Vortman, President of InSightec. "Results
from the clinical studies showed that patients, many of whom who
suffered for years from neurological disorders, experienced immediate
symptom improvement with a high safety profile. These patients are now
better able to conduct activities of daily living and are also less
dependent on external caregiver support."
"ExAblate® Neuro offers a non-invasive treatment with no ionizing
radiation, which treats tissue deep in the brain through an intact
skull. MR guided Focused ultrasound (MRgFUS) combines therapeutic
acoustic ultrasound waves with continuous MRI guidance," added Eyal
Zadicario, Vice President of R&D and Director of InSightec's Neuro
program. "The MRI enables physicians to visualize, plan, guide,
monitor and control the treatment while the ultrasound acoustic energy
destroys the targeted tissue in the brain."
InSightec recently received its second ExAblate FDA approval for the
treatment of painful bone metastases in patients who are unable or
unwilling to undergo radiation. This is in addition to FDA approval for
the treatment of uterine fibroids received in 2004. The CE marking
enables ExAblate Neuro to be sold in Europe.
InSightec Ltd. is privately held by Elbit Imaging, General Electric, and MediTech
Advisors. Founded in 1999 InSightec developed ExAblate to transform
MRI-guided Focused Ultrasound (MRgFUS) into a clinically viable
technology. ExAblate has won several awards for innovation and its
potential to help mankind including The Wall Street Journal Technology Innovation Awards and the European Union's IST grand prize. TIME magazine recently named Focused Ultrasound as "one of 50 best
inventions". For more information about treatment centers and brain
disorders please visit: http://www.insightec.com .
SOURCE: InSightec Ltd
For further information: